Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Elevated serum phosphate (hyperphosphatemia) in chronic kidney disease (CKD) increases cardiovascular risk.
• Standard treatments like protein restriction and dialysis are often insufficient to control hyperphosphatemia.
• Existing phosphate binders (calcium-based, resin-based) can cause adverse effects like hypercalcemia and ectopic mineralization.

Purpose of the Study:

• To review clinical and experimental data on lanthanum carbonate as a novel phosphate binder.
• To assess the safety and efficacy of lanthanum carbonate in CKD patients.
• To evaluate the long-term effects of lanthanum carbonate on bone, vasculature, and brain.

Main Methods:

• Review of recent clinical studies and experimental data on lanthanum carbonate.
• Analysis of lanthanum bioavailability, metabolism, and toxicity.
• Examination of clinical trial data up to 6 years of follow-up.

Main Results:

• Lanthanum carbonate is a non-calcium, non-resin phosphate binder.
• Lanthanum exhibits extremely low bioavailability and a distinct metabolism, avoiding aluminum-like toxicity.
• Clinical studies show no toxic effects of lanthanum carbonate with up to 6 years of follow-up.

Conclusions:

• Lanthanum carbonate is a safe and effective option for managing hyperphosphatemia in advanced CKD.
• Its unique pharmacokinetic profile minimizes risks associated with traditional phosphate binders.
• Further evaluation of its long-term impact on bone, vasculature, and brain is warranted.